These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31917143)

  • 1. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.
    Romoli M; Perucca E; Sen A
    Epilepsy Behav; 2020 Feb; 103(Pt A):106861. PubMed ID: 31917143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence for adjunct pyridoxine (vitamin B6) for the treatment of behavioral adverse effects associated with levetiracetam: A systematic review.
    Besag FMC; Vasey MJ; Sen A
    Epilepsy Behav; 2023 Mar; 140():109065. PubMed ID: 36791631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridoxine Add-On Treatment for the Control of Behavioral Adverse Effects Induced by Levetiracetam in Children: A Case-Control Prospective Study.
    Marino S; Vitaliti G; Marino SD; Pavone P; Provvidenti S; Romano C; Falsaperla R
    Ann Pharmacother; 2018 Jul; 52(7):645-649. PubMed ID: 29442544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results.
    Major P; Greenberg E; Khan A; Thiele EA
    Epilepsy Behav; 2008 Oct; 13(3):557-9. PubMed ID: 18647662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of Levetiracetam-Induced Behavioral Side Effects by Pyridoxine. A Randomized Double Blind Controlled Study.
    Mahmoud A; Tabassum S; Al Enazi S; Lubbad N; Al Wadei A; Al Otaibi A; Jad L; Benini R
    Pediatr Neurol; 2021 Jun; 119():15-21. PubMed ID: 33823377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
    Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
    Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.
    Bedetti C; Romoli M; Maschio M; Di Bonaventura C; Nardi Cesarini E; Eusebi P; Siliquini S; Dispenza S; Calabresi P; Costa C
    Eur J Neurol; 2017 Oct; 24(10):1283-1289. PubMed ID: 28796376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study.
    Lob K; Bassell-Hawkins J; Patil R; Nie D; Bartolini L
    Epilepsy Behav; 2022 Sep; 134():108839. PubMed ID: 35839645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy?
    Sarangi SC; Kaur N; Tripathi M
    Epilepsy Behav; 2019 Nov; 100(Pt A):106439. PubMed ID: 31574428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
    Kanemura H; Sano F; Aihara M
    Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Levetiracetam in Paediatrics: A Systematic Review.
    Egunsola O; Choonara I; Sammons HM
    PLoS One; 2016; 11(3):e0149686. PubMed ID: 26930201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials.
    Gan J; Ma D; Xiong T
    BMJ Open; 2019 Jul; 9(7):e029811. PubMed ID: 31296513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies.
    Rashid M; Rajan AK; Chhabra M; Kashyap A
    Seizure; 2020 Feb; 75():101-109. PubMed ID: 31931437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral effects of levetiracetam mitigated by pyridoxine.
    Davis GP; McCarthy JT; Magill DB; Coffey B
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):209-11. PubMed ID: 19364300
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychiatric Symptoms of Patients With Epilepsy: Characteristics of Psychiatric Adverse Events by Novel Antiepileptic Medications].
    Kanemoto K; Nishida T; Hasegawa N
    Brain Nerve; 2023 Apr; 75(4):375-389. PubMed ID: 37037510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy.
    Thelengana A; Shukla G; Srivastava A; Singh MB; Gupta A; Rajan R; Vibha D; Pandit AK; Prasad K
    Epilepsy Res; 2019 Feb; 150():58-65. PubMed ID: 30641352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.